The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1267 articles
Researchers at The University of Queensland have uncovered how wasps and frogs produce bradykinin-like peptides that evolved separately from vertebrate versions to trigger pain in predators. These 'evolutionary doppelgängers' derive from toxin genes, overturning decades of scientific assumptions. This discovery highlights convergent evolution in animal defenses.
A new Stanford Medicine study uncovers why GLP-1 receptor agonists may not work as well for some Type 2 diabetes patients: certain genetic variants lead to GLP-1 resistance. Carried by about 10% of the population, these variants result in higher but less effective GLP-1 levels. This could guide faster, personalized treatment switches.
Ozempic isn't just transforming waistlines—it's igniting a surge in hot sauce sales like Tapatío's. As millions embrace GLP-1 drugs, cravings for bold flavors skyrocket, propelling L.A.'s iconic brand into national expansion under new owners Highlander Partners. This is the untold story of family legacy meeting metabolic health trends.
Scientists have uncovered why Ozempic and similar GLP-1 drugs don't work for everyone: genetic variants in the PAM gene cause GLP-1 resistance in about 10% of people. Despite higher GLP-1 levels, these individuals show reduced drug effectiveness in lowering blood sugar. This breakthrough could pave the way for personalized treatment strategies.
New research reveals a hidden genetic reason why Ozempic fails for some: GLP-1 resistance linked to PAM gene variants affecting 10% of the population. Despite higher GLP-1 levels, these individuals show reduced drug efficacy in lowering blood sugar. Discover the study's findings from humans, mice, and clinical trials.
New studies uncover genetic variations in GLP1R and GIPR genes that predict better weight loss and higher side effect risks with GLP-1 drugs like Ozempic and Mounjaro. Cardiac protections from semaglutide appear separate from obesity reduction. A mouse study highlights noncoding DNA mutations' profound developmental impacts.
A large study presented in San Diego reveals semaglutide use is not associated with higher risk of non-arteritic anterior ischemic optic neuropathy (NAION) in patients with overweight or obesity. In fact, it lowered NAION risk by 64% among those with type 2 diabetes compared to non-GLP-1 therapies. Experts emphasize continued monitoring of blood sugar and blood pressure.
Jelon Smart from Savannah dropped 110 pounds on Ozempic—but credits her intensive workout regimen too. Facing severe ankle swelling from Achilles tendinitis at 285 pounds, she transformed her life. Doctors remind GLP-1 users: movement and mental health are essential alongside medication.
It starts with an Instagram reel from an influencer hyping potent weight-loss peptides. Soon, Indians dive into YouTube explainers, Reddit threads, and chat groups, ending with unapproved shipments from China. Hundreds rely on these cheaper alternatives to pricey Mounjaro and Ozempic amid GLP-1 plateaus.
